Medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale)

In 2024, medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) trade exhibited strong growth, with global flows reaching $1,564,705 and a three-year compound annual growth rate of +64.3% (five-year: -3.0%). The all-time peak of $4,870,753 was recorded in 2002; the current level is 68% below that high-water mark.

Over the 30-year observation window (1995–2024), 59% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is strengthening (+64.6% acceleration).

The supply side is concentrated (Herfindahl-Hirschman Index 0.393). The three largest exporters — Ireland ($1.9M), Netherlands ($1.8M), and United States ($802.3K) — collectively dominate supply flows. The leading exporter has grown at +393.6% over the last three years.

On the demand side, importer concentration is concentrated (HHI 0.392). The three largest import markets are Vietnam ($1.1M), United Kingdom ($748.4K), and United States ($619.8K). The largest importing market sources from 2 different supplying countries.

The dominant trade corridor is Ireland → Vietnam at $1.1M, representing 100.0% of the importer's total demand.

The volatility score for medicaments: containing alkaloids or their derivatives, containing norephedrine or its salts, for therapeutic or prophylactic uses, (not packaged for retail sale) is 82 out of 100, classified as high. This product exhibits above-average trade variability, making it important to monitor supply chain resilience and price exposure.

For market entrants, strong demand tailwinds create a favourable entry environment. The concentrated supply structure suggests high barriers but also potential opportunity if dominant suppliers face disruption or capacity constraints.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.